• Susan G. Komen Applauds HHS Decision to Cover Breast Cancer Prevention Drugs

    Chemoprevention Drugs to Be Covered As Preventive Medication under Affordable Care Act

    DALLAS, TX – January 9, 2014 – The world’s leading breast cancer organization today applauded the U.S. Department of Health and Human Services’ decision to include coverage for certain breast cancer prevention drugs.

    The important announcement means that patients at increased risk of breast cancer can now receive chemoprevention drugs, including tamoxifen and raloxifene, without a co-pay or other out-of-pocket expense.

    The new coverage comes after the recommendations from the U.S. Preventive Services Task Force that patients at an increased risk of breast cancer (due to age, family history or other factors) can take the preventive medications to decrease their risk of developing the disease.

    “This is a significant milestone in America's health care system” said Judy Salerno, President and CEO of Susan G. Komen. “This expanded coverage will empower patients across the country to make informed decisions about their breast cancer risk without the added weight of financial concerns.”

    In addition to this new coverage, the Affordable Care Act currently requires insurers to cover mammography, with no cost-sharing, every one to two years for women starting at age 40. Medicare fully pays for mammograms once every 12 months with no upper age limit.

    Komen has also consistently advocated for coverage for quality cancer care for all women. Breast cancer prevention has been a key focus of Komen’s research portfolio for many years, with almost $47 million invested into prevention research.